Respiratory syncytial virus infection (RSV) is currently a widespread disease worldwide, which is severe in the elderly and young children, leading to severe complications and even death. No specific etiotropic therapy currently exists. Several groups of researchers around the world are actively developing antiviral agents against MS infection, but none of them is yet suitable for widespread use in clinical practice. Diffractic acid is one of the major secondary metabolites of many lichens and belongs to the class of depsides. There are few studies devoted to its biological activity. This compound is known to have moderate antibacterial and insecticidal properties, as well as antiulcer and hepatoprotective activity. Our group developed an isolation technique and isolated diffractic acid from a mixture of lichens of the genus Usnea. Tests on the ability to inhibit RSV reproduction in vitro showed that diffractaic acid has significant antiviral activity against RSV: EC50 = 4.8 μM, CC50 = 221.9 μM, SI = 46.
Previous Article in event Previous Article in session
Next Article in event
Silver(I) complexes as potential anticancer drugs: synthesis, characterization, and in vitro studiesNext Article in session
Diffractic acid isolation and its activity against respiratory syncytial virus
Published: 01 November 2023 by MDPI in 9th International Electronic Conference on Medicinal Chemistry session Natural Products and Biopharmaceuticals
https://doi.org/10.3390/ECMC2023-15574 (registering DOI)
Keywords: diffractic acid; anti- RSV agents